Research News and Research

RSS

Cambrex first-quarter sales down 6.4% to $56.2 million

Cambrex Corporation reports first quarter results for the period ended March 31, 2010.

4 May 2010

Supreme Court decides federal doctors cannot be sued for prisoner's death

The Los Angeles Times: "The family of a Los Angeles-area immigrant who languished in federal detention for nearly a year while a cancerous growth went untreated cannot sue government doctors for medical neglect, the Supreme Court ruled Monday."

4 May 2010

Living with a dementia sufferer may affect spouse

In a new study researchers have revealed that partners of patients suffering from dementia or degeneration of memory and other mental faculties are six times more likely to develop the condition themselves.

4 May 2010

MAP Pharmaceuticals reports net loss $14.1 million for first-quarter 2010

MAP Pharmaceuticals, Inc. today announced financial results for the first quarter ended March 31, 2010.

4 May 2010

Techne Corporation's consolidated net earnings up 17.2% for quarter ended March 31, 2010

Techne Corporation's consolidated net earnings for the quarter ended March 31, 2010 increased 17.2% to $32.4 million or $.87 per diluted share compared with $27.6 million or $.74 per diluted share for the quarter ended March 31, 2009. The increase in net earnings for the quarter was primarily due to a $4.7 million tax benefit, equating to $.12 per share, resulting from a foreign exchange tax loss on Techne's repatriation of 50 million pound sterling from R&D Systems Europe to its U.S. based parent.

From BiosPacific, Inc. 4 May 2010

Glycos Biotechnologies announces international expansion into Malaysia

Glycos Biotechnologies, Inc., an emerging biochemical company pioneering metabolic engineering and microbiology innovations for the production of sustainable biochemicals, today announced the company's international expansion into Malaysia.

4 May 2010

Fresenius Medical Care's first-quarter net revenue up 13% to $2,882 million

Fresenius Medical Care AG & Co. KGaA, the world's largest provider of dialysis products and services, today announced its results for the first quarter of 2010.

4 May 2010

Roche announces Health Canada approval for ACTEMRA to treat RA

Roche today announced that Health Canada has approved ACTEMRA(TM) (tocilizumab) to treat patients with rheumatoid arthritis (RA), a chronic, progressive inflammatory disease of the joints and surrounding tissues that is associated with intense pain, irreversible joint destruction and systemic complications, such as fatigue and anemia.

4 May 2010

Celldex reports net loss of $6.6 million for first-quarter 2010

Celldex Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2010. Celldex reported a net loss of $6.6 million, or $0.21 per share, for the first quarter of 2010 compared to a net loss of $7.7 million, or $0.49 per share, for the first quarter of 2009. At March 31, 2010, Celldex reported cash, cash equivalents and marketable securities of $75.4 million, which the Company believes will be sufficient to meet estimated working capital requirements and fund operations into 2012.

4 May 2010

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Synageva BioPharma Corp., a privately held biopharmaceutical company, today announced its filing with the U.S. Food and Drug Administration (FDA) requesting orphan drug designation for its program, SBC-102. This program is an enzyme replacement therapy in preclinical development to treat lysosomal acid lipase (LAL) deficiency, also known as Wolman disease or cholesteryl ester storage disease (CESD), a condition for which there is currently no effective treatment.

4 May 2010

Australia to introduce plain cigarette packaging

Cigarettes in Australia will soon have to be sold in plain packaging to prevent consumers - and particularly children - from being influenced by tobacco advertising.

4 May 2010

Generic Flomax launch drives Impax Laboratories first-quarter total revenue to $323.3 million

Impax Laboratories, Inc. today reported significant growth in the first quarter of 2010 due to an increase in sales from its Global product sales channel. Total revenue increased $264.4 million to $323.3 million driven by the successful March 2 exclusive launch of generic Flomax® ($176.2 million of revenue and $167.9 million of gross profit) and continued strong sales of generic Adderall XR® for which there were no comparable amounts in the first quarter 2009, as well as increased sales of the Company's fenofibrate products.

4 May 2010

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Par Pharmaceutical Companies, Inc. today reported results for the first quarter ended March 31, 2010.

4 May 2010

Techne declares dividend of $0.26 per share for quarter ended March 31, 2010

Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.26 per share for the quarter ended March 31, 2010. The quarterly dividend will be payable May 28, 2010 to all common shareholders of record on May 14, 2010. Future cash dividends will be considered by the Board of Directors on a quarterly basis.

From BiosPacific, Inc. 4 May 2010

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it plans to initiate patient recruitment for a cancer immunotherapy study by year end. The pilot study seeks to demonstrate an improved immune function in cancer patients as a result of the Aethlon Hemopurifier removing tumor-secreted exosomes from the circulatory system.

4 May 2010

HPV test recommended for national cervical cancer screening programmes

Two studies suggest that testing for the human papillomavirus (HPV) - the major cause of cervical cancer - could be used in national cervical cancer screening programmes.

4 May 2010

Early treatment of ROP for high-risk premature babies can improve vision: ETROP study

Scientists have shown that through eye examinations, doctors can identify infants who are most likely to benefit from early treatment for a potentially blinding eye condition called retinopathy of prematurity, resulting in better vision for many children.

4 May 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended March 31, 2010.

4 May 2010

Chances of surviving lung cancer much lower in England than in Norway or Sweden: Scientists

The chances of surviving lung cancer are much lower in England than they are in Norway or Sweden, scientists at King's College London have found.

4 May 2010

GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11.3M in 2009

GTx, Inc. today reported financial results for the first quarter of 2010. The net income for the first quarter ended March 31, 2010 was $44.3 million compared with a net loss of $11.3 million for the same period in 2009. Net income for the current period included the recognition of approximately $54.9 million in collaboration revenue due to the termination of our license and collaboration agreement with Merck & Co., Inc in March 2010.

4 May 2010

Research News and Research

Cambrex first-quarter sales down 6.4% to $56.2 million

Supreme Court decides federal doctors cannot be sued for prisoner's death

Living with a dementia sufferer may affect spouse

MAP Pharmaceuticals reports net loss $14.1 million for first-quarter 2010

Techne Corporation's consolidated net earnings up 17.2% for quarter ended March 31, 2010

Glycos Biotechnologies announces international expansion into Malaysia

Fresenius Medical Care's first-quarter net revenue up 13% to $2,882 million

Roche announces Health Canada approval for ACTEMRA to treat RA

Celldex reports net loss of $6.6 million for first-quarter 2010

Synageva BioPharma seeks FDA orphan drug designation for SBC-102 enzyme replacement therapy

Australia to introduce plain cigarette packaging

Generic Flomax launch drives Impax Laboratories first-quarter total revenue to $323.3 million

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Techne declares dividend of $0.26 per share for quarter ended March 31, 2010

Aethlon Medical plans to initiate patient recruitment for cancer immunotherapy study

HPV test recommended for national cervical cancer screening programmes

Early treatment of ROP for high-risk premature babies can improve vision: ETROP study

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Chances of surviving lung cancer much lower in England than in Norway or Sweden: Scientists

GTx reports net income of $44.3M for first-quarter 2010 compared with net loss of $11.3M in 2009

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence